Cargando…

Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a high mortality rate worldwide. The percentage of HCC patients with vascular invasion at the time of initial HCC diagnosis is 10%–40%. According to most guidelines, HCC with vascular invasion is classified as advanced st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zunyi, Zhang, Erlei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169581/ https://www.ncbi.nlm.nih.gov/pubmed/37180144 http://dx.doi.org/10.3389/fimmu.2023.1073531

Ejemplares similares

Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
por: Du, Jiajia, et al.
Publicado: (2023)

Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy
por: Zhang, Zunyi, et al.
Publicado: (2023)

EXO1 Plays a Carcinogenic Role in Hepatocellular Carcinoma and is related to the regulation of FOXP3
por: Yang, Guang, et al.
Publicado: (2020)

Effectiveness comparison of indocyanine green retention test with the cirrhotic severity scoring in evaluating the pathological severity of liver cirrhosis in patients with hepatocellular carcinoma and Child-Pugh grade A liver function
por: Gu, Jin, et al.
Publicado: (2020)

Development of conversion therapy for advanced hepatocellular carcinoma
por: Matsuki, Ryota, et al.
Publicado: (2023)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Comprehensive Analysis Identifies and Validates the Tumor Microenvironment Subtypes to Predict Anti-Tumor Therapy Efficacy in Hepatocellular Carcinoma
por: Zhang, Haohan, et al.
Publicado: (2022)

Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
por: Zhang, Wei, et al.
Publicado: (2023)

Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma
por: Zhang, Ze, et al.
Publicado: (2023)

Construction of a ceRNA Network and a Prognostic lncRNA Signature associated with Vascular Invasion in Hepatocellular Carcinoma based on Weighted Gene Co-Expression Network Analysis
por: Tao, Haisu, et al.
Publicado: (2021)

Recent update on comprehensive therapy for advanced hepatocellular carcinoma
por: Wang, Hui, et al.
Publicado: (2021)

Radiation therapy in the era of immune treatment for hepatocellular carcinoma
por: Chen, Lingjuan, et al.
Publicado: (2023)

Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma
por: Li, Duguang, et al.
Publicado: (2023)

Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview
por: Sun, Hui-Chuan, et al.
Publicado: (2021)

Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma
por: Zhao, Ming, et al.
Publicado: (2023)

Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma
por: Zhang, Lu, et al.
Publicado: (2021)

H-TEX-mediated signaling between hepatocellular carcinoma cells and macrophages and exosome-targeted therapy for hepatocellular carcinoma
por: Yu, Sihang, et al.
Publicado: (2022)

Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma
por: Ding, Lin, et al.
Publicado: (2022)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
por: Liu, Junjie, et al.
Publicado: (2022)

Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma
por: Liang, Linjun, et al.
Publicado: (2023)

Construction and Comprehensive Analysis of ceRNA Networks and Tumor-Infiltrating Immune Cells in Hepatocellular Carcinoma With Vascular Invasion
por: Cai, Shijiao, et al.
Publicado: (2022)

Prognosticators of hepatocellular carcinoma with intrahepatic vascular invasion
por: Lo, Yuan-Chen, et al.
Publicado: (2019)

Prognostic analysis of hepatocellular carcinoma with macrovascular invasion after liver resection and a successful case of conversion therapy
por: Ji, Mengling, et al.
Publicado: (2022)

PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study
por: Su, Ke, et al.
Publicado: (2022)

Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
por: Xin, Yujing, et al.
Publicado: (2022)

Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study
por: Li, Xin, et al.
Publicado: (2022)

Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
por: Feng, Duan, et al.
Publicado: (2017)

Bibliometric study of immunotherapy for hepatocellular carcinoma
por: Li, Zhiyi, et al.
Publicado: (2023)

Conversion therapy for massive hepatocellular carcinoma: A case report and literature review
por: Zhou, Zheyu, et al.
Publicado: (2023)

Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma—A Real-World Multicenter Study (RICE-Retro)
por: Huang, Shujie, et al.
Publicado: (2022)

Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy
por: Ohya, Yuki, et al.
Publicado: (2020)

Non-Invasive Imaging of Vascular Inflammation
por: Ammirati, Enrico, et al.
Publicado: (2014)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
por: Xie, Fucun, et al.
Publicado: (2022)

Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy
por: Qiao, Wenying, et al.
Publicado: (2022)

Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study
por: Pan, Yangxun, et al.
Publicado: (2023)

Emerging therapies in advanced hepatocellular carcinoma
por: Medavaram, Sowmini, et al.
Publicado: (2018)

Comprehensive analysis of FOXM1 immune infiltrates, m6a, glycolysis and ceRNA network in human hepatocellular carcinoma
por: Xu, Ziwu, et al.
Publicado: (2023)

Exploring a four-gene risk model based on doxorubicin resistance-associated lncRNAs in hepatocellular carcinoma
por: Zhang, Zunyi, et al.
Publicado: (2022)

Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy
por: Ho, Won Jin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0fmrtp19pj2hg2tsk72rsmsi0i